Medical management of neurofibromatosis 1: A cross-sectional study of 383 patients

Journal of the American Academy of Dermatology

Volumn 49, Issue 3, 2003, Pages 440-444

  Drappier, Jean Christophe ^a   Khosrotehrani, Kiarash ^a   Zeller, Jacques ^a   Revuz, Jean ^a   Wolkenstein, Pierre ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE;

ADULT; ARTICLE; BRAIN ARACHNOID CYST; BRAIN TUMOR; CARCINOID; CLINICAL FEATURE; DATA BASE; DIAGNOSTIC IMAGING; EPILEPSY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SPINAL CORD COMPRESSION; VALIDATION PROCESS;

EID: 0041856236     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0190-9622(03)01481-6     Document Type: Article

References (20)

1. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis. JAMA 1997;278:51-7.
2. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997; 70:138-43.
3. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Hum Genet 2001;68:1110-8.
4. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000;105:608-14.
5. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000;151:33-40.
6. Huson SM. What level of care for the neurofibromatoses? Lancet 1999;353:1114-6.
7. Ablon J. Gender response to neurofibromatosis 1. Soc Sci Med 1996;42:99-109.
8. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplège A. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 2001;137:1421-5.
9. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med 1981;305:1617-27.
10. Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis: a clinical and population study in southeast Wales. Brain 1988;111:1355-81.
11. National Institutes of Health Consensus Development Conference. Neurofibromatosis: conference statement. Arch Neurol 1988;45:575-8.
12. Wolkenstein P, Freche B, Zeller J, Revuz J. Usefulness of screening investigations in neurofibromatosis type 1: a study of 152 patients. Arch Dermatol 1996;132:1333-6.
13. Wolkenstein P, Durand-Zaleski I, Moreno JC, Zeller J, Hemery F, Revuz J. Cost evaluation of the medical management of neurofibromatosis 1: a prospective study on 201 patients. Br J Dermatol 2000;142:1166-70.
14. Pinson S, Creange A, Barbarot S, Stalder JF, Chaix Y, Rodriguez C, et al. Neurofibromatosis 1: recommendations for management. Ann Dermatol Venereol 2001;128:567-75.
15. Friedman JM, Birch P, Greene C. National Neurofibromatosis Foundation international database. Am J Med Genet 1993;45: 88-91.
16. Riccardi VM, Kleiner B. Neurofibromatosis: a neoplastic birth defect with two age peaks of severe problems. Birth Defects Orig Artic Ser 1977;13:131-8.
17. Cnossen MH, de Goede-Bolder A, van den Broek KM, Waasdorp CM, Oranje AP, Stroink H, et al. A prospective 10 year follow up study of patients with neurofibromatosis type 1. Arch Dis Chilc 1998;78:408-12.
18. Eichenfield LF, Levy ML, Paller AS, Riccardi VM. Guidelines of care for neurofibromatosis type 1: American Academy of Dermatology guidelines/outcomes committee. J Am Acad Dermatol 1997;37:625-30.
19. Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994;125:63-6.
20. Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force. Ann Neurol 1997;41:143-9.